| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/16/2009 | US20090098544 Marker molecules associated with lung tumors |
| 04/16/2009 | US20090098528 Method for determining early HCV seroconversion |
| 04/16/2009 | US20090098214 Skin-revitalizing cosmetic composition |
| 04/16/2009 | US20090098205 pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES |
| 04/16/2009 | US20090098200 Compositions comprising lipophilic active compounds and method for their preparation |
| 04/16/2009 | US20090098195 Influenza virus infection suppressor |
| 04/16/2009 | US20090098184 Processes and systems for loading medical implants with simulative growth agents |
| 04/16/2009 | US20090098175 Methods and compositions for delivery of growth factor to fibrous connective tissue |
| 04/16/2009 | US20090098165 Methods and compositions for immunization against chlamydial infection and disease |
| 04/16/2009 | US20090098148 High efficiency tissue-specific compound delivery system using streptavadin-protein a fusion protein |
| 04/16/2009 | US20090098146 Methods to diagnose a required regulation of trophoblast invasion |
| 04/16/2009 | US20090098137 Combinations of therapeutic agents for treating cancer |
| 04/16/2009 | US20090098132 Composition and method for treating lupus nephritis |
| 04/16/2009 | US20090098131 Compositions and methods for the treatment of immune related diseases |
| 04/16/2009 | US20090098129 Member of the TNF Ligand Family |
| 04/16/2009 | US20090098127 Agents Capable of Downregulating an MSF-A DEPENDENT HIF-1ALPHA and Use Thereof in Cancer Treatment |
| 04/16/2009 | US20090098123 Hcv coreceptor and methods of use thereof |
| 04/16/2009 | US20090098120 Compositions and methods for the treatment of immune related diseases |
| 04/16/2009 | US20090098119 Antidotes for factor xa inhibitors and methods of using the same |
| 04/16/2009 | US20090098117 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 04/16/2009 | US20090098115 Cell lines and animal models of HER2 expressing tumors |
| 04/16/2009 | US20090098114 ALK7 and myostatin inhibitors and uses thereof |
| 04/16/2009 | US20090098113 Activin-ActRIIa antagonists and uses for promoting bone growth |
| 04/16/2009 | US20090098111 Methods for modulating checkpoint activation through TopBP1 |
| 04/16/2009 | US20090098110 Injectable forms of solid-forming crosslinked bioelastic biopolymers for local drug delivery |
| 04/16/2009 | US20090098108 means of delivering the GLP-1 peptide in a sustained manner; obesity related disorders |
| 04/16/2009 | US20090098106 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-kB ACTIVITY |
| 04/16/2009 | US20090098105 Treatment of neurodegenerative diseases by the use of scd4 inhibitors |
| 04/16/2009 | US20090098104 Method for Diagnosing Cardiovascular Diseases |
| 04/16/2009 | US20090098103 Modified factor VII polypeptides and uses thereof |
| 04/16/2009 | US20090098101 Compositions and methods for ribonuclease-based therapeutics |
| 04/16/2009 | US20090098100 Hormonally up-regulated, neu-tumor-associated kinase |
| 04/16/2009 | US20090098097 Composition for normalizing blood pressure |
| 04/16/2009 | US20090098096 Agent for correcting stress-inducing neuro-mediator, neuro-endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 04/16/2009 | US20090098091 Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis |
| 04/16/2009 | US20090098086 Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| 04/16/2009 | US20090098085 Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| 04/16/2009 | US20090098084 Parp inhibitor compounds, compositions and methods of use |
| 04/16/2009 | US20090098083 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 04/16/2009 | US20090098064 Method of treating pulmonary edema or pulmonary inflammation |
| 04/16/2009 | US20090098054 Methods and compositions relating to promoter regulation by muc1 and klf proteins |
| 04/16/2009 | US20090098051 Bacillus thuringiensis toxin |
| 04/16/2009 | US20090098050 Calcium binding peptides |
| 04/16/2009 | US20090098049 Targeting transducible molecules to specific cell types |
| 04/16/2009 | US20090095293 Dry powder inhalation system for transpulmonary administration |
| 04/16/2009 | US20090095289 Increased Dosage Metered Dose Inhaler |
| 04/16/2009 | CA2739719A1 Laminins, derivatives, and compositions including same and method for their therapeutic use |
| 04/16/2009 | CA2702470A1 Functional lipid constructs |
| 04/16/2009 | CA2702366A1 Compositions affecting hyaluronic acid mediated activity |
| 04/16/2009 | CA2702217A1 Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| 04/16/2009 | CA2702190A1 Injectable radio-opaque compositions for tissue augmentation |
| 04/16/2009 | CA2702173A1 Preparation for treating heart disease used in cell therapy |
| 04/16/2009 | CA2702082A1 Aqueous ophthalmic formulations |
| 04/16/2009 | CA2702057A1 Rapid acting injectable insulin compositions |
| 04/16/2009 | CA2702043A1 Compositions and methods for ribonuclease-based therapies |
| 04/16/2009 | CA2701482A1 Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
| 04/16/2009 | CA2701369A1 Modified growth hormone polypeptides |
| 04/16/2009 | CA2701362A1 Soluble fragments of influenza virus pb2 protein capable of binding rna-cap |
| 04/16/2009 | CA2701189A1 Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| 04/16/2009 | CA2700236A1 Anticancer composition comprising plant stem cell line derived from taxus cambium or procambium |
| 04/16/2009 | CA2699257A1 Cgrp as a therapeutic agent |
| 04/16/2009 | CA2699169A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | CA2699168A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | CA2699163A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699090A1 Combination therapy with antibody-drug conjugates |
| 04/16/2009 | CA2699088A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699087A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699084A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | CA2699083A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2698326A1 Antibody targeting osteoclast-related protein siglec-15 |
| 04/15/2009 | EP2048505A2 Method for early recognition of the seroconversion of an antibody to hepatitis C |
| 04/15/2009 | EP2048235A2 Synthetic Mammalian Alpha-N-Acetylglucosaminidase and Genetic Sequences Encoding Same |
| 04/15/2009 | EP2048160A1 Tumor antigen based on products of the tumor suppressor gene WT1 |
| 04/15/2009 | EP2048159A1 T cell receptor display |
| 04/15/2009 | EP2048158A1 Glycosylated human alpha interferon muteins, method for obtaining them and use |
| 04/15/2009 | EP2048157A1 Polynucleotide encoding the rg1 polypeptide |
| 04/15/2009 | EP2048156A1 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin |
| 04/15/2009 | EP2047867A1 ACE2 activation for treatment of heart, lung and kidney disease and hypertension |
| 04/15/2009 | EP2047866A1 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 04/15/2009 | EP2047859A1 Treatment of ischemic disease using erythropoietin |
| 04/15/2009 | EP2047858A1 Combination products for treating cancer |
| 04/15/2009 | EP2047857A1 Agent for injection purposes comprising antibiotic, and solution for injection comprising the agent |
| 04/15/2009 | EP2047848A1 Method of treating genetic disease caused by nonsense mutation |
| 04/15/2009 | EP2046958A1 Cleavage of bip by subtilase cytotoxin |
| 04/15/2009 | EP2046948A1 Activated fibroblasts for treating tissue and/or organ damage |
| 04/15/2009 | EP2046828A2 Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same |
| 04/15/2009 | EP2046826A2 Exendin fusion proteins |
| 04/15/2009 | EP2046825A1 Antimicrobial peptide derived from galanin message associated peptide (gmap) |
| 04/15/2009 | EP2046823A1 Post-translationally modified neurotrophins |
| 04/15/2009 | EP2046822A1 Molecular probe for sphingolipids |
| 04/15/2009 | EP2046821A1 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins |
| 04/15/2009 | EP2046814A2 Minimized small peptides with high affinity for factor viii and factor viii-like proteins |
| 04/15/2009 | EP2046812A1 A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide |
| 04/15/2009 | EP2046778A1 Multifunctional bioactive compounds |
| 04/15/2009 | EP2046407A1 Implantable preparation, useful more particularly for tissue complement and cicatrisation |
| 04/15/2009 | EP2046386A2 Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction |
| 04/15/2009 | EP2046380A2 Human endogenous retrovirus polypeptide compositions and methods of use thereof |
| 04/15/2009 | EP2046373A2 Crystallized oxalate decarboxylase and methods of use |
| 04/15/2009 | EP2046372A2 Factor viia analogues with increased activity for treating thrombocytopenia |
| 04/15/2009 | EP2046371A2 Factor viia analogues with increased activity for treating thrombocytopenia |